Not only dopamine D 2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 2, 2012, Pages 332-338

  Wang, Di ^a   Wong, Hei Kiu ^a   Zhang, Li ^b   McAlonan, Grainne M ^c   Wang, Xiao Min ^d   Sze, Stephen Cho Wing ^a   Feng, Yi Bin ^a   Zhang, Zhang Jin ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d NATIONAL INSTITUTE OF NURSING RESEARCH   (United States)

Author keywords

Antipsychotics; D 2 receptors; Dopamine; Herbal medicine; Hyperprolactinemia; Peony Glycyrrhiza Decoction (PGD)

Indexed keywords

ALBIFLORIN; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; ESTRADIOL; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; HALOPERIDOL; LIQUIRITIGENIN; LIQUIRITIN; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PAEONIA GLYCYRRHIZA EXTRACT; PAEONIFLORIN; PLANT EXTRACT; PROGESTERONE; PROLACTIN; UNCLASSIFIED DRUG; DOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; ENDOCRINE DISEASE; ESTRADIOL BLOOD LEVEL; FEMALE; GLYCYRRHIZA; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PAEONIA; PHYTOCHEMISTRY; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTIN SYNTHESIS; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; TUMOR CELL; ANIMAL; BIOSYNTHESIS; BLOOD; CELL LINE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG POTENTIATION; HERB DRUG INTERACTION; METABOLISM; METHODOLOGY; PC12 CELL; PHYTOTHERAPY; RABBIT; SECRETION (PROCESS); SPRAGUE DAWLEY RAT;

ANIMALS; BROMOCRIPTINE; CELL LINE; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; GLYCYRRHIZA; HALOPERIDOL; HERB-DRUG INTERACTIONS; HYPERPROLACTINEMIA; METOCLOPRAMIDE; PAEONIA; PC12 CELLS; PHYTOTHERAPY; PLANT EXTRACTS; PROGESTERONE; PROLACTIN; RABBITS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2;

EID: 84867024470     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.07.005     Document Type: Article

References (48)

1. Andreassen O.A., Jørgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?. Prog Neurobiol 2000, 61:525-541.
2. Armanini D., Mattarello M.J., Fiore C., Bonanni G., Scaroni C., Sartorato P., et al. Licorice reduces serum testosterone in healthy women. Steroids 2004, 69:763-766.
3. Biller B.M., Luciano A., Crosignani P.G., Molitch M., Olive D., Rebar R., et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999, 44(12S):1075-1084.
4. Chiasson K., Daoust B., Levesque D., Martinoli M.G. Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+ -induced toxicity in PC12 cells. Neurotox Res 2006, 10:31-42.
5. Chinese Pharmacopoeia Commission Pharmacopoeia of the People's Republic of China (2010 Edition) 2010, Chemical Industry Press, Beijing, China.
6. Costa A.M., Lima M.S., Mari Jde J. A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo Med J 2006, 124:291-297.
7. Davidson J.S., Baumgarten I.M. Glycyrrhetinic acid derivatives: a novel class of inhibitors of gap-junctional intercellular communication. Structure-activity relationships. J Pharmacol Exp Ther 1988, 246:1104-1107.
8. Demaria J.E., Nagy G.M., Lerant A.A., Fekete M.I., Levenson C.W., Freeman M.E. Dopamine transporters participate in the physiological regulation of prolactin. Endocrinology 2000, 141:366-374.
9. Ernst E. Risks of herbal medicinal products. Pharmacoepidemiol Drug Saf 2004, 13:767-771.
10. Fazeli G., Oli R.G., Schupp N., Stopper H. The role of the dopamine transporter in dopamine-induced DNA damage. Brain Pathol 2011, 21:237-248.
11. Fitzgerald P., Dinan T.G. Prolactin and dopamine: what is the connection?. J Psychopharmacol 2008, 22(2S):12-19.
12. Fukui M., Kitagawa Y., Nakamura N., Yoshikawa T. Glycyrrhizin and serum testosterone concentrations in male patients with type 2 diabetes. Diabetes Care 2003, 26:2962.
13. Giacomini D., Haedo M., Gerez J., Druker J., Páez-Pereda M., Labeur M., et al. Differential gene expression in models of pituitary prolactin-producing tumoral cells. Horm Res 2009, 71(Suppl. 2):88-94.
14. Halbreich U., Kahn L.S. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract 2003, 9:344-353.
15. Hwang I.K., Lim S.S., Choi K.H., Yoo K.Y., Shin H.K., Kim E.J., et al. Neuroprotective effects of roasted licorice, not raw form, on neuronal injury in gerbil hippocampus after transient forebrain ischemia. Acta Pharmacol Sin 2006, 27:959-965.
16. Inder W.J., Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry 2011, 45:830-837.
17. Iriti M., Vitalini S., Fico G., Faoro F. Neuroprotective herbs and foods from different traditional medicines and diets. Molecules 2010, 15:3517-3555.
18. Jang E.Y., Hwang M., Yoon S.S., Lee J.R., Kim K.J., Kim H.C., et al. Liquiritigenin decreases selective molecular and behavioral effects of cocaine in rodents. Curr Neuropharmacol 2011, 9:30-34.
19. Judd A.M., Login I.S., Kovacs K., Ross P.C., Spangelo B.L., Jarvis W.D., et al. Characterization of the MMQ cell, a prolactin-secreting clonal cell line that is responsive to dopamine. Endocrinology 1988, 123:2341-2350.
20. Kane J.M., Correll C.U. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010, 71:1115-1124.
21. Koyama T., Ohara M., Ichimura M., Saito M. Effect of Japanese kampo medicine on hypothalamic-pituitary-ovarian function in women with ovarian insufficiency. Am J Chin Med 1988, 16:47-55.
22. Laszczyńska M., Słuczanowska-Głabowska S., Piasecka M., Skowron J., Debińska-Szymańska T. Germ cells with nuclear DNA fragmentation related to apoptotic cells in rat testis in experimental hyperprolactinemia induced by metoclopramide. Folia Histochem Cytobiol 2002, 40:163-164.
23. Lin B. Polyphenols and Neuroprotection against Ischemia and Neurodegeneration. Mini Rev Med Chem 2011, Epub ahead of print.
24. Liu H.Q., Zhang W.Y., Luo X.T., Ye Y., Zhu X.Z. Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A1 receptor. Br J Pharmacol 2006, 148:314-325.
25. Liu D.Z., Zhu J., Jin D.Z., Zhang L.M., Ji X.Q., Ye Y., et al. Behavioral recovery following sub-chronic paeoniflorin administration in the striatal 6-OHDA lesion rodent model of Parkinson's disease. J Ethnopharmacol 2007, 112:327-332.
26. Mao Q.Q., Zhong X.M., Li Z.Y., Huang Z. Paeoniflorin protects against NMDA-induced neurotoxicity in PC12 cells via Ca2+ antagonism. Phytother Res 2011, 25:681-685.
27. Marken P.A., Haykal R.F., Fisher J.N. Management of psychotropic-induced hyperprolactinemia. Clin Pharmacol 1992, 11:851-856.
28. Missale C., Castelletti L., Boroni F., Memo M., Spano P. Epidermal growth factor induces the functional expression of dopamine receptors in the GH3 cell line. Endocrinology 1991, 128:13-20.
29. Moore H., Grace A.A. A role for electrotonic coupling in the striatum in the expression of dopamine receptor-mediated stereotypies. Neuropsychopharmacology 2002, 27:980-992.
30. Nolan E.B., Harrison L.M., Lahoste G.J., Ruskin D.N. Behavioral synergism between D(1) and D(2) dopamine receptors in mice does not depend on gap junctions. Synapse 2007, 61:279-287.
31. Sakamoto K., Wakabayashi K. Inhibitory effect of glycyrrhetinic acid on testosterone production in rat gonads. Endocrinol Jpn 1988, 35:333-342.
32. Takahashi K., Kitao M. Effect of TJ-68 (Shakuyaku-Kanzo-To) on polycystic ovarian disease. Int J Fertil Menopausal Stud 1994, 39:69-76.
33. Takahashi K., Yoshino K., Shirai T., Nishigaki A., Araki Y., Kitao M. Effect of a traditional herbal medicine (Shakuyaku-Kanzo-To) on testosterone secretion in patients with polycystic ovary syndrome detected by ultrasound. Nippon Sanka Fujinka Gakkai Zasshi 1988, 40:789-792.
34. Takeuchi T., Nishii O., Okamura T., Yaginuma T. Effect of paeoniflorin, glycyrrhizin and glycyrrhetic acid on ovarian androgen production. Am J Chin Med 1991, 19:73-78.
35. Tamaya T., Sato S., Okada H. Inhibition by plant herb extracts of steroid bindings in uterus, liver and serum of the rabbit. Acta Obstet Gynecol Scand 1986, 65:839-842.
36. Tanaka T. Effects of herbal medicines on menopausal symptoms induced by gonadotropin-releasing hormone agonist therapy. Clin Exp Obstet Gynecol 2001, 28:20-23.
37. Tsai T.Y., Wu S.N., Liu Y.C., Wu A.Z., Tsai Y.C. Inhibitory action of L-type Ca2+ current by paeoniflorin, a major constituent of peony root, in NG108-15 neuronal cells. Eur J Pharmacol 2005, 523:16-24.
38. Ukai W., Ozawa H., Tateno M., Hashimoto E., Saito T. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J Neural Transm 2004, 111:667-681.
39. Usuki S. Effects of hachimijiogan, tokishakuyakusan and keishibukuryogan on the corpus luteum function and weights of various organs in vivo. Am J Chin Med 1987, 15:99-108.
40. Usuki S. Effects of herbal components of tokishakuyakusan on progesterone secretion by corpus luteum in vitro. Am J Chin Med 1991, 19:57-60.
41. Whorwood C.B., Sheppard M.C., Stewart P.M. Licorice inhibits 11 etahydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology 1993, 132:2287-2292.
42. Xu J.X. Treatment of hyperprolactinemic impotence by Jiawei Shaoyao Gancao Tang: a clinical observation of 58 cases. Contemp Chin Medicine (Xin-Zhong-Yi) 2003, 35:21-22.
43. Yaginuma T., Izumi R., Yasui H., Arai T., Kawabata M. Effect of traditional herbal medicine on serum testosterone levels and its induction of regular ovulation in hyperandrogenic and oligomenorrheic women. Nippon Sanka Fujinka Gakkai Zasshi 1982, 34:939-944.
44. Yamada K., Kanba S., Murata T., Fukuzawa M., Terashi B., Yagi G., et al. Effectiveness of shakuyaku-kanzo-to in neuroleptic-induced hyperprolactinemia: a preliminary report. Psychiatry Clin Neurosci 1996, 50:341-342.
45. Yamada K., Kanba S., Murata T., Fukuzawa M., Terashi B., Yagi G., et al. Effectiveness of herbal medicine (Shakuyaku-Kanzo-To) for neuroleptic-induced hyperprolactinemia. J Clin Psychopharmacol 1997, 17:234-235.
46. Yamada K., Kanba S., Yagi G., Asai M. Herbal medicine (Shakuyaku-Kanzo-To) in the treatment of risperidone-induced amenorrhea. J Clin Psychopharmacol 1999, 19:380-381.
47. Yuan H.N., Wang C.Y., Sze C.W., Tong Y., Tan Q.R., Feng X.J., et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol 2008, 28:264-370.
48. Zhang Z.J., Tan Q.R., Zhen X.C., Tong Y. The potential benefits of herbal medicines for schizophrenia: from empirical observations to clinical trials (chapter 16). Clinical Trials in Psychopharmacology 2010, 311-335. Wiley-Blackwell, UK. M. Hertzman, L. Adler (Eds.).